Hereditary Cancer Testing Market Expected to Reach $10.1 Billion by 2031—Allied Market Research

According to a new report published by Allied Market Research, titled, “Hereditary Cancer Testing Market," The hereditary cancer testing market was valued at $3.5 billion in 2021, and is estimated to reach $10.1 billion by 2031, growing at a CAGR of 11.6% from 2022 to 2031.

Hereditary cancer is any cancer caused by an inherited gene mutation. An inherited gene means that it is passed from the parent to the child within a family. The harmful variants in some genes are known to be associated with an increased risk of developing cancer. Genetic testing helps to estimate an individual, the chance of developing cancer in his of her lifetime. This can be done by searching for specific changes in the genes, chromosomes or proteins. These include breast cancer, ovarian cancer, colon cancer, thyroid cancer, prostate cancer, pancreatic cancer, melanoma, kidney cancer and stomach cancer. Hereditary cancer  test helps in predicting risk of a particular cancer type. Most breast and ovarian cancers are not caused by inherited mutations, so genetic testing does not help most women with a family health history of breast and ovarian cancer. Genetic testing also does not identify the cause for some hereditary breast and ovarian cancers, because the genes affected in these cancers are not yet known. Hence, the genetic counseling before genetic testing for hereditary breast and ovarian cancer is important to determine whether person and his family members are likely enough to have a mutation and that it is worth getting tested. 

The key drivers of the hereditary cancer testing market size are rise in geriatric population, increase in incidence of cancer across the globe, and increase in the government expenditure on healthcare. Moreover, increase in awareness regarding the cancer testing and favorable reimbursement policies also contribute in the growth of the hereditary cancer testing market size. For instance, according to data of World Health Organization (WHO), about 22,61,419 new breast cancer cases were recorded in 2020. Moreover, according to the data of breast cancer organization, in January 2021, there were more than 3.8 million women with a history of breast cancer in the U.S. However, lack of skilled professionals and high cost of the tests are expected to hinder the growth of hereditary cancer testing market. Conversely, the high growth potential in untapped emerging economies is expected to create lucrative opportunities for the market.

On the basis of cancer type, the market is classified into breast cancer, gastric cancer, ovarian cancer, prostate cancer, colorectal cancer, other cancers. The colorectal cancer segment is projected to exhibit the fastest market growth during the hereditary cancer testing market forecast period, owing to the increase in the number of breast cancer patients, increase in the cancer testing products available in the market.

On the basis of test type, the market is classified into predictive testing and diagnostic testing. The predictive testing segment is anticipated to grow at the highest rate, owing to upsurge in demand of predictive testing performed in the hospitals and rise in the prevalence of various cancer types. Moreover, the rise in the preference of the predictive testing also helps in the growth of this segment in the hereditary cancer testing market share.

On the basis of end user, the market is classified into the market is classified into diagnostic centers, hospitals and clinics. Moreover, the hospitals segment is sub-classified by type as private and public. The diagnostic centers segment is anticipated to grow at the highest rate, owing to the hereditary cancer testing market trends like increase in the number of diagnostic centers and increase in the adoption of hereditary cancer testing in the diagnostic centers. Furthermore, the rise in number of cancer patients also contributes in the growth of diagnostic centers segment in the hereditary cancer testing market share.

On the basis of region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA). In 2021, North America was the dominant region and is expected to remain dominant throughout the forecast period, owing to high prevalence rate of cancer, increase in geriatric population, and surge in number of diagnostic procedures in the region. However, Asia-Pacific is expected to witness the highest CAGR of 13.8% during the analysis period, owing to the presence of high populace countries such as India and China, which in turn increases the prevalence rate of cancer types, and the increase in number of product launch and product approvals.

KEY FINDINGS OF STUDY

• By cancer type, the breast cancer segment accounted for major share of the global hereditary cancer testing industry in 2021.
• By test type, the predictive testing segment is anticipated to grow with the highest CAGR during the hereditary cancer testing market analysis period.
• By end user, the diagnostic centers segment is anticipated to grow with the highest CAGR during the forecast period.
• Asia-Pacific is anticipated to grow at the highest rate during the hereditary cancer testing industry analysis period.